Trial Profile
A trial to examine the role of rituximab in treatment-resistant myasthenia gravis (MG)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 May 2016
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; Therapeutic Use
- 03 May 2016 New trial record
- 21 Apr 2016 Interim results (n=15) presented at the 68th Annual Meeting of the American Academy of Neurology